Zacks: Brokerages Expect Atara Biotherapeutics (ATRA) Will Announce Earnings of -$0.91 Per Share

Wall Street analysts expect Atara Biotherapeutics (NASDAQ:ATRA) to announce earnings of ($0.91) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Atara Biotherapeutics’ earnings. The lowest EPS estimate is ($0.96) and the highest is ($0.85). Atara Biotherapeutics reported earnings per share of ($0.88) during the same quarter last year, which would suggest a negative year-over-year growth rate of 3.4%. The company is expected to issue its next earnings results on Thursday, May 3rd.

According to Zacks, analysts expect that Atara Biotherapeutics will report full-year earnings of ($3.62) per share for the current financial year, with EPS estimates ranging from ($3.75) to ($3.49). For the next financial year, analysts expect that the company will post earnings of ($3.84) per share, with EPS estimates ranging from ($4.27) to ($3.41). Zacks Investment Research’s EPS calculations are a mean average based on a survey of research firms that cover Atara Biotherapeutics.

How to Become a New Pot Stock Millionaire

Atara Biotherapeutics (NASDAQ:ATRA) last announced its earnings results on Tuesday, February 27th. The biotechnology company reported ($1.15) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($1.15).

A number of analysts have commented on ATRA shares. Canaccord Genuity reiterated a “buy” rating on shares of Atara Biotherapeutics in a research note on Friday, December 29th. ValuEngine upgraded shares of Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Friday, December 29th. Citigroup upgraded shares of Atara Biotherapeutics from a “sell” rating to a “neutral” rating and set a $18.00 price target for the company in a research note on Wednesday, January 3rd. BidaskClub upgraded shares of Atara Biotherapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, January 11th. Finally, Cowen started coverage on shares of Atara Biotherapeutics in a research note on Friday, January 26th. They issued an “outperform” rating for the company. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and five have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $33.80.

Shares of ATRA stock opened at $35.15 on Friday. Atara Biotherapeutics has a one year low of $11.80 and a one year high of $49.90.

In other news, Director Carol Giltner Gallagher sold 1,183 shares of the firm’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $46.50, for a total transaction of $55,009.50. Following the completion of the sale, the director now owns 111,286 shares in the company, valued at approximately $5,174,799. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO John Mcgrath sold 13,000 shares of the firm’s stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $47.07, for a total transaction of $611,910.00. Following the sale, the chief financial officer now owns 99,056 shares of the company’s stock, valued at approximately $4,662,565.92. The disclosure for this sale can be found here. In the last quarter, insiders sold 315,324 shares of company stock valued at $11,379,838. Corporate insiders own 16.20% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the company. SG Americas Securities LLC acquired a new stake in shares of Atara Biotherapeutics during the 3rd quarter worth about $142,000. Russell Investments Group Ltd. acquired a new stake in shares of Atara Biotherapeutics during the 3rd quarter worth about $170,000. MetLife Investment Advisors LLC acquired a new stake in shares of Atara Biotherapeutics during the 4th quarter worth about $217,000. Dimensional Fund Advisors LP lifted its stake in shares of Atara Biotherapeutics by 2.9% during the 2nd quarter. Dimensional Fund Advisors LP now owns 21,718 shares of the biotechnology company’s stock worth $304,000 after buying an additional 610 shares during the last quarter. Finally, Virtus Fund Advisers LLC acquired a new stake in shares of Atara Biotherapeutics during the 4th quarter worth about $434,000. Institutional investors own 76.88% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Zacks: Brokerages Expect Atara Biotherapeutics (ATRA) Will Announce Earnings of -$0.91 Per Share” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this news story can be read at https://www.dispatchtribunal.com/2018/04/09/zacks-brokerages-expect-atara-biotherapeutics-atra-will-announce-earnings-of-0-91-per-share.html.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. The company is developing tabelecleucel, an advanced T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.

Get a free copy of the Zacks research report on Atara Biotherapeutics (ATRA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply